Chen, Kun-HungKun-HungChenKO-JEN LIFang, Yao-FanYao-FanFangSONG-CHOU HSIEHChen, Ying-ChouYing-ChouChenLee, Chyou-ShenChyou-ShenLeeLuo, Shue-FenShue-FenLuoCheng, Tien-TsaiTien-TsaiChengTsai, Wen ChanWen ChanTsaiLo, Yu-ChenYu-ChenLoLan, Joung-LiangJoung-LiangLan2025-06-112025-06-112024-07https://scholars.lib.ntu.edu.tw/handle/123456789/729972To evaluate real-world abatacept retention and clinical outcomes in patients with rheumatoid arthritis in Taiwan. This prospective, observational study enrolled patients with rheumatoid arthritis aged ≥20 years who received abatacept in real-world practice. The primary endpoint was the abatacept retention rate at 24 months. Patients were categorized into subgroups based on abatacept treatment status and previous biological disease-modifying antirheumatic drug (bDMARD) therapy. Risk factors affecting abatacept retention were determined by regression analysis. A total of 212 patients were enrolled. The overall abatacept retention rate at 24 months among all patients was 59.9% (95% confidence interval 53.0%-66.6%). Patients who were ongoing users of abatacept and bDMARD-naïve had the highest retention rate (76.3%); of these, 31.6% achieved low disease activity or remission after 2 years. Previous treatment with bDMARDs was associated with an increased risk of abatacept discontinuation (hazard ratio 1.99; p = .002). The most common reasons for abatacept discontinuation were drug switch (11.3%) and loss to follow-up (6.1%). Abatacept was well-tolerated with no new safety signals. The 24-month retention rate of abatacept was 59.9%; abatacept was associated with improved clinical outcomes and was well-tolerated in the real-world setting in Taiwan.enTaiwanabataceptclinical practicereal‐worldretentionrheumatoid arthritis[SDGs]SDG3journal article10.1111/1756-185X.1519939010815